Stock 2137 BRII BIOSCIENCES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Brii Biosciences Limited

Equities

2137

KYG1645A1094

Delayed Hong Kong S.E.
Other stock markets
 09:08:42 28/06/2024 BST 		5-day change 1st Jan Change
1.01 HKD -0.98% Intraday chart for Brii Biosciences Limited -7.34% -55.70%
06-10 Brii Biosciences Presents Hepatitis B Drug Data at European Medical Conference MT
06-07 Brii Biosciences Limited Announces New Data from Two Phase 2 Studies Evaluating BRII-179 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024
PR
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies
PR
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
AQ
Brii Biosciences Announces Agreements To Acquire VBI Vaccines' IP Rights In BRII-179
AQ
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies
PR
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer
PR
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 in Combination with PEG-IFN for the Treatment of Chronic Hepatitis B
AQ
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B
PR
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results
PR
Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure
PR
Brii Biosciences Provides Latest Clinical Development and Corporate Updates
PR
Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693
PR
Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023
PR
Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders
PR
Brii Bio Publishes 2022 Environmental, Social and Governance Report
PR
Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022
PR
Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression
PR
Brii Biosciences Announces China Leadership Team Changes
AQ
Brii Biosciences Appoints Taiyin Yang to Board of Directors, Strengthening Product Quality Oversight to Support Company Momentum
PR
Brii Biosciences Provides Corporate Update and Reports 2022 Interim Results
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2137 Stock
  4. News Brii Biosciences Limited
  5. Press Releases